SovetkinaA, NadirR, ScalfariA, et al.Development of autoimmune thyroid disease in multiple sclerosis patients post-alemtuzumab improves treatment response. J Clin Endocrinol Metab, 2020; 105:e3392–e3399; doi: 10.1210/clinem/dgaa453
2.
MonzaniF, CaraccioN, DardanoA, et al.Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med, 2004; 3:199–210; doi: 10.1007/s10238-004-0026-3
3.
Rodriguez de VeraP, Garcia-GonzálezJJ, Ravé-GarciaR, et al.Graves' disease induced by alemtuzumab in relapsing-remitting multiple sclerosis patients: An observational study in a reference center. J Endocrinol Invest, 2022; 45(10):1977–1990; doi: 10.1007/s40618-022-01832-4
4.
PopescuV, BeirinckxA, DecallonneB.Post-alemtuzumab Graves' disease remitting after switch to ocrelizumab. Acta Neurol Belg, 2022; 122:1117–1120; doi: 10.1007/s13760-022-01962-9
5.
LaneLC, CheethamTD, PerrosP, et al.New therapeutic horizons for Graves' hyperthyroidism. Endocr Rev, 2020; 41:873–884; doi: 10.1210/endrev/bnaa022
